RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma

被引：0
|
作者：
Petrylak, D. P. [1 ]
Chi, K. N. [2 ]
Drakaki, A. [3 ]
Sternberg, C. N. [4 ,5 ]
de Wit, R. [6 ]
Nishiyama, H. [7 ]
Yu, E. Y. [8 ]
Castellano, D. [9 ]
Hussain, S. [10 ]
Percent, I. J. [11 ]
Flechon, A. [12 ]
Bamias, A. [13 ]
Van der Heijden, M. S. [14 ]
Matsubara, N. [15 ]
Alekseev, B.
Walgren, R. A. [16 ]
Hamid, O. [17 ]
Zimmermann, A. H. [17 ]
Bell-Mcguinn, K. M. [17 ]
Powles, T. [18 ]
机构：
[1] Yale Univ, Sch Med, Med Oncol, New Haven, CT USA
[2] BC Canc Agcy, Med, Vancouver, BC, Canada
[3] Univ Calif Los Angeles, Med Ctr, Med & Urol, Los Angeles, CA 90024 USA
[4] San Camillo Hosp, Dept Oncol, Rome, Italy
[5] Forlanini Hosp, Dept Oncol, Rome, Italy
[6] Erasmus MC Canc Inst, Oncol, Rotterdam, Netherlands
[7] Univ Tsukuba, Oncol, Tsukuba, Ibaraki, Japan
[8] Univ Washington, Med, Seattle, WA 98195 USA
[9] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain
[10] Univ Liverpool, Oncol, Liverpool, Merseyside, England
[11] Florida Canc Specialists, Oncol, Port Charlotte, FL USA
[12] Ctr Leon Berard, Oncol, Lyon, France
[13] Univ Athens, Therapeut Oncol, Athens, Greece
[14] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Mol Carcinogenesis, Amsterdam, Netherlands
[15] Natl Canc Ctr Hosp East, Oncol, Chiba, Japan
[16] PA Herzen Moscow Oncol Res Inst, Oncol, Moscow, Russia
[17] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[18] Queen Mary Univ London, Barts Canc Inst, Med Oncol, London, England
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA4-PR
引用
收藏
页数：1
相关论文
共 50 条
  • [1] RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results
    Petrylak, D. P.
    Sternberg, C. N.
    Drakaki, A.
    de Wit, R.
    Nishiyama, H.
    Necchi, A.
    Castellano, D.
    Bamias, A.
    Chi, K. N.
    van der Heijden, M. S.
    Matsubara, N.
    Hussain, S.
    Flechon, A.
    Alekseev, B. Y.
    Yu, E. Y.
    Walgren, R. A.
    Russo, F.
    Zimmermann, A. H.
    Bell-Mcguinn, K. M.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC)
    Matsubara, Nobuaki
    Petrylak, Daniel Peter
    Nishiyama, Hiroyuki
    Su, Wen-Pin
    Lee, Jae-Lyun
    Li, Jian-Ri
    Walgren, Richard A.
    Hamid, Oday
    Zimmermann, Annamaria
    Bell-McGuinn, Katherine M.
    Gao, Ling
    Homma, Gosuke
    Yana, Ikuo
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Quality-of-life (QoL) in RANGE: A phase 3 study of ramucirumab (RAM) plus docetaxel (DOC) versus placebo (P) plus DOC in platinum-refractory locally advanced or metastatic urothelial carcinoma (UC).
    Necchi, Andrea
    Nishiyama, Hiroyuki
    Matsubara, Nobuaki
    Lee, Jae-Lyun
    Petrylak, Daniel Peter
    De Wit, Ronald
    Drakaki, Alexandra
    Liepa, Astra M.
    Zimmermann, Annamaria
    Bell-McGuinn, Katherine M.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [4] Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)
    Andrea Necchi
    Hiroyuki Nishiyama
    Nobuaki Matsubara
    Jae-Lyun Lee
    Daniel P. Petrylak
    Ronald de Wit
    Alexandra Drakaki
    Astra M. Liepa
    Huzhang Mao
    Katherine Bell-McGuinn
    Thomas Powles
    BMC Urology, 20
  • [5] Ramucirumab (RAM) exposure-response (ER) relationship in RANGE: A randomized phase III trial of RAM plus docetaxel (DOC) versus placebo (P) plus DOC in advanced platinum-refractory urothelial carcinoma (UC) patients (pts).
    De Wit, Ronald
    Powles, Thomas
    Castellano, Daniel E.
    Necchi, Andrea
    Lee, Jae-Lyun
    Van der Heijden, Michiel Simon
    Matsubara, Nobuaki
    Bamias, Aristotelis
    Flechon, Aude
    Sternberg, Cora N.
    Drakaki, Alexandra
    Yu, Evan Y.
    Hamid, Oday
    Zimmermann, Annamaria H.
    Gao, Ling
    Long, Amanda
    Walgren, Richard A.
    Bell-McGuinn, Katherine M.
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)
    Necchi, Andrea
    Nishiyama, Hiroyuki
    Matsubara, Nobuaki
    Lee, Jae-Lyun
    Petrylak, Daniel P.
    de Wit, Ronald
    Drakaki, Alexandra
    Liepa, Astra M.
    Mao, Huzhang
    Bell-McGuinn, Katherine
    Powles, Thomas
    BMC UROLOGY, 2020, 20 (01)
  • [7] Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
    Petrylak, Daniel P.
    de Wit, Ronald
    Chi, Kim N.
    Drakaki, Alexandra
    Sternberg, Cora N.
    Nishiyama, Hiroyuki
    Castellano, Daniel
    Hussain, Syed
    Flechon, Aude
    Bamias, Aristotelis
    Yu, Evan Y.
    van der Heijden, Michiel S.
    Matsubara, Nobuaki
    Alekseev, Boris
    Necchi, Andrea
    Geczi, Lajos
    Ou, Yen-Chuan
    Coskun, Hasan Senol
    Su, Wen-Pin
    Hegemann, Miriam
    Percent, Ivor J.
    Lee, Jae-Lyun
    Tucci, Marcello
    Semenov, Andrey
    Laestadius, Fredrik
    Peer, Avivit
    Tortora, Giampaolo
    Safina, Sufia
    Garcia del Muro, Xavier
    Rodriguez-Vida, Alejo
    Cicin, Irfan
    Harputluoglu, Hakan
    Widau, Ryan C.
    Liepa, Astra M.
    Walgren, Richard A.
    Hamid, Oday
    Zimmermann, Annamaria H.
    Bell-McGuinn, Katherine M.
    Powles, Thomas
    LANCET, 2017, 390 (10109): : 2266 - 2277
  • [8] Re: Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Metastatic Urothelial Carcinoma after Platinum-Based Therapy (RANGE): A Randomised, Double-Blind, Phase 3 Trial
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2019, 201 (06): : 1052 - 1053
  • [9] Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial.
    Drakaki, Alexandra
    Kirby, Conor J.
    Van der Heijden, Michiel Simon
    Petrylak, Daniel Peter
    Powles, Thomas
    Chi, Kim N.
    Flechon, Aude
    Necchi, Andrea
    Geczi, Lajos
    Lee, Jae-Lyun
    Gakis, Georgios
    Bracarda, Sergio
    Chowdhury, Simon
    Lin, Chia-Chi
    Keizman, Daniel
    Vaishampayan, Ulka N.
    Liepa, Astra M.
    Zimmermann, Annamaria
    Bell-McGuinn, Katherine M.
    Castellano, Daniel E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [10] RANGE: A randomized, blinded, placebo-controlled phase III study of ramucirumab plus docetaxel in 2nd-line urothelial carcinoma
    Nishiyama, Hiroyuki
    Asou, Hiroya
    Richard, Walgren
    ANNALS OF ONCOLOGY, 2015, 26 : 144 - 144
12345